StockData
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Larimar Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.12+0.14 (+6.80%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 4, 2026Before market open–$-0.30–
Q1 FY2026
Ended Mar 31, 2026
May 14, 2026Before market open–$-0.31–
Q4 FY2025
Ended Dec 31, 2025
Mar 19, 2026Before market open–$-0.73–
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025Before market open–––
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open–$-0.41–
Q1 FY2025
Ended Mar 31, 2025
Apr 30, 2025Before market open–$-0.46–
Q4 FY2024
Ended Dec 31, 2024
Mar 24, 2025Before market open–$-0.45–
Q3 FY2024
Ended Sep 30, 2024
Oct 30, 2024Before market open–$-0.24–
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024Before market open–$-0.34–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024Before market open–$-0.27–
Q4 FY2023
Ended Dec 31, 2023
Mar 14, 2024After market close–$-0.30–

Press releases

Announcements Larimar Therapeutics filed with the SEC